Profile data is unavailable for this security.
About the company
Abliva AB is a Sweden-based company involved in pharmaceutical industry. The Company focuses on the development of novel treatments for primary mitochondrial diseases.
- Revenue in SEK (TTM)137.00k
- Net income in SEK-102.13m
- Incorporated2000
- Employees6.00
- LocationAbliva ABMedicon Village, Scheeletorget 1LUND 223 81SwedenSWE
- Phone+46 462756220
- Fax+46 468888348
- Websitehttps://abliva.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biovica International AB | 7.25m | -115.45m | 221.95m | 27.00 | -- | 2.48 | -- | 30.61 | -1.73 | -1.73 | 0.1055 | 1.06 | 0.0584 | 17.30 | 4.76 | 226,593.80 | -92.98 | -51.94 | -110.37 | -58.18 | -394.72 | -576.01 | -1,592.15 | -2,217.41 | 3.47 | -- | 0.0721 | -- | 115.49 | 19.39 | -12.97 | -- | -54.31 | -- |
| Thor Medical ASA | 0.00 | -17.89m | 228.66m | 1.00 | -- | 0.9123 | -- | -- | -0.0873 | 0.021 | 0.00 | 1.11 | 0.00 | -- | -- | 0.00 | -9.82 | -79.17 | -10.54 | -113.94 | -- | -- | -- | -- | -- | -- | 0.0035 | -- | -- | -- | -- | -- | -- | -- |
| Kancera AB | 0.00 | -53.07m | 235.10m | 5.00 | -- | 2.83 | -- | -- | -0.5955 | -0.5955 | 0.00 | 0.6849 | 0.00 | -- | -- | 0.00 | -56.73 | -54.82 | -66.40 | -66.21 | -- | 96.28 | -- | -7,249.06 | -- | -- | 0.00 | -- | -- | -- | -23.64 | -- | -- | -- |
| Xbrane Biopharma AB | 191.89m | -340.89m | 261.24m | 71.00 | -- | 0.8578 | -- | 1.36 | -1.01 | -1.26 | 0.3403 | 0.1991 | 0.209 | 0.7028 | 24.13 | 2,063,301.00 | -37.14 | -40.98 | -66.96 | -67.24 | 43.32 | -- | -177.65 | -364.40 | 1.07 | -20.51 | 0.357 | -- | 314.33 | 63.42 | -91.10 | -- | 60.02 | -- |
| Ascelia Pharma AB | 0.00 | -61.78m | 261.82m | 13.00 | -- | 2.85 | -- | -- | -1.26 | -1.26 | 0.00 | 0.9554 | 0.00 | -- | -- | 0.00 | -52.75 | -- | -65.92 | -- | -- | -- | -- | -- | -- | -40.42 | 0.4167 | -- | -- | -- | 16.72 | -- | -- | -- |
| Intervacc AB | 9.78m | -102.66m | 287.80m | 15.00 | -- | 1.42 | -- | 29.43 | -1.36 | -1.36 | 0.1291 | 2.68 | 0.0355 | 3.19 | 1.62 | 651,933.30 | -37.23 | -17.62 | -40.38 | -18.77 | -551.10 | -243.59 | -1,049.76 | -626.90 | 2.90 | -- | 0.0006 | -- | -17.23 | -25.79 | -60.31 | -- | -38.72 | -- |
| Abliva AB | 137.00k | -102.13m | 296.26m | 6.00 | -- | 2.88 | -- | 2,162.51 | -0.0928 | -0.0928 | 0.0001 | 0.0638 | 0.0013 | -- | 0.0062 | -- | -93.81 | -74.59 | -103.87 | -86.98 | -35,826.28 | -- | -74,542.34 | -65,958.89 | -- | -- | 0.00 | -- | 341.94 | 93.89 | -12.02 | -- | -19.74 | -- |
| Annexin Pharmaceuticals AB (publ) | 0.00 | -52.36m | 304.86m | 4.00 | -- | 8.46 | -- | -- | -0.1873 | -0.1873 | 0.00 | 0.0676 | 0.00 | -- | -- | 0.00 | -162.59 | -125.42 | -220.41 | -151.33 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.17 | -- | -- | -- |
| Xintela AB | 381.00k | -40.83m | 307.13m | -- | -- | -- | -- | 806.12 | -0.0817 | -0.0817 | 0.0008 | -0.0319 | 0.0306 | -- | 0.0493 | -- | -327.65 | -181.06 | -- | -391.61 | 100.00 | -- | -10,717.06 | -235,894.00 | -- | -203.91 | -- | -- | -- | -45.54 | 18.32 | -- | -61.47 | -- |
| Herantis Pharma Oyj | 0.00 | -6.95m | 322.71m | 10.00 | -- | 13.93 | 13.70 | -- | -0.0146 | -0.0146 | 0.00 | 0.1012 | 0.00 | -- | -- | 0.00 | -13.93 | -80.46 | -27.32 | -104.37 | -- | -- | -- | -- | -- | -- | 0.0145 | -- | -- | -- | 103.00 | -- | -- | -- |
| Lifecare ASA | 15.52m | -49.93m | 329.43m | 32.00 | -- | 2.77 | -- | 21.23 | -0.3152 | -0.3152 | 0.0999 | 0.632 | 0.1564 | -- | -- | 502,995.00 | -50.29 | -40.00 | -56.16 | -45.26 | -- | -- | -321.48 | -175.53 | -- | -- | 0.0918 | -- | -40.88 | 30.29 | -101.74 | -- | -- | -- |
| Alzinova AB | 300.00k | -18.12m | 331.70m | 5.00 | -- | 1.97 | -- | 1,105.65 | -0.332 | -0.332 | 0.0055 | 1.89 | 0.0025 | -- | 0.4752 | 60,000.00 | -15.15 | -10.77 | -15.91 | -11.27 | -2,621.00 | -- | -6,039.67 | -18,447.90 | -- | -392.89 | 0.0076 | -- | -- | -- | -25.92 | -- | 15.81 | -- |
| Bergenbio ASA | 502.23k | -149.81m | 338.17m | 15.00 | -- | 2.00 | -- | 673.33 | -5.37 | -5.37 | 0.018 | 4.48 | 0.0023 | -- | 0.0411 | 20,840.00 | -67.73 | -66.15 | -85.55 | -78.74 | -- | -- | -29,828.21 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
| Curasight A/S | -43.27m | -48.34m | 340.56m | 4.00 | -- | 17.64 | -- | -- | -1.51 | -1.51 | -1.35 | 0.6008 | -0.7563 | -- | -- | -7,107,500.00 | -84.49 | -24.61 | -111.31 | -26.01 | -- | -- | -- | -- | -- | -32.26 | 0.4439 | -- | -123.97 | -- | -42.62 | -- | -- | -- |
| Lytix Biopharma AS | -96.40bn | -96.40bn | 367.28m | 10.00 | -- | 6.43 | -- | -- | -- | -- | -- | 1.19 | -- | -- | -- | -- | -- | -56.91 | -- | -65.83 | -- | -- | -- | -771.78 | -- | -- | 0.0482 | -- | -63.82 | 63.94 | -56.77 | -- | -- | -- |
| SynAct Pharma AB | 0.00 | -165.96m | 368.36m | 5.00 | -- | 1.97 | -- | -- | -4.75 | -4.75 | 0.00 | 4.53 | 0.00 | -- | -- | 0.00 | -61.52 | -125.17 | -67.60 | -151.70 | -- | -- | -- | -- | -- | -231.85 | 0.0076 | -- | -- | -- | -117.54 | -- | -- | -- |
Data as of Sep 19 2024. Currency figures normalised to Abliva AB's reporting currency: Swedish Krona SEK
1.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 31 Aug 2024 | 7.44m | 0.46% |
| Skandia Investment Management ABas of 31 Jul 2024 | 6.67m | 0.41% |
| FCG Fonder ABas of 30 Aug 2024 | 4.72m | 0.29% |
| SEB Investment Management ABas of 30 Aug 2024 | 3.45m | 0.21% |
| Storebrand Asset Management ASas of 30 Jun 2024 | 811.31k | 0.05% |
| Skandia Fonder ABas of 31 Jul 2024 | 245.36k | 0.02% |
More ▼
Data from 30 Jun 2024 - 30 Aug 2024Source: FactSet Research Systems Inc.
